CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
急性淋巴细胞白血病的新型嵌合抗原受体靶点与构建体：超越 CD19
英文原题：Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19.
查看英文原题
Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
急性淋巴细胞白血病（ALL）是成人中第二常见的急性白血病，复发/难治性（R/R）B细胞系ALL（B-ALL）预后较差。抗CD19嵌合抗原受体（CAR）T细胞疗法在RR B-ALL中显示出优异的缓解率，但大多数患者由于CAR-T 细胞疗法持久性差或其他肿瘤相关逃逸机制而复发。此外，抗CD19 CAR-T 细胞疗法会引起细胞因子释放综合征和神经毒性等几种严重副作用。在这篇综述中，我们将讨论用于治疗RR B-ALL的新型CAR靶点、CAR构建体以及增强CAR的各种策略。此外，我们还讨论了一些为减少CAR副作用而开发的新策略。
展开英文摘要原文
Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults with a poor prognosis with relapsed or refractory (R/R) B-cell lineage ALL (B-ALL). Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown excellent response rates in RR B-ALL, but most patients relapse due to poor persistence of CAR T-cell therapy or other tumor-associated escape mechanisms.
In addition, anti-CD19 CAR T-cell therapy causes several serious side effects such as cytokine release syndrome and neurotoxicity. In this review, we will discuss novel CAR targets, CAR constructs, and various strategies to boost CARs for the treatment of RR B-ALL.
In addition, we discuss a few novel strategies developed to reduce the side effects of CAR.
论文信息
- 作者
- Acharya L、Garg A、Rai M、Kshetri R、Grewal US、Dhakal P
- 单位
- Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.United States
- 文献类型
- 综述
- 期刊
- Journal of investigative medicine : the official publication of the American Federation for Clinical Research2024 Jan
- 原文标识
- PubMed 37497999 · DOI 10.1177/10815589231191811